{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:46:45Z","timestamp":1794469605346,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ARCAGY Research; AstraZeneca; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc"},{"name":"Amiculum Business Services Limited"},{"name":"AstraZeneca and Merck Sharp & Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We analyzed health-related quality of life (HRQoL) and time until definitive HRQoL deterioration for patients with newly diagnosed advanced ovarian cancer receiving olaparib plus bevacizumab or placebo plus bevacizumab in PAOLA-1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Health-related QoL and time until definitive HRQoL deterioration, prespecified secondary endpoints, were assessed by European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30) and Ovarian Cancer module (QLQ-OV28) at baseline and then every 12\u2009weeks for 2\u2009years. Health-related QoL and time until definitive HRQoL deterioration by homologous recombination deficiency status and effect of progression on HRQoL were post hoc analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 806 patients were randomly assigned (olaparib plus bevacizumab n\u2009=\u2009537; placebo plus bevacizumab n\u2009=\u2009269). There were no clinically meaningful between-group differences in adjusted mean global change from baseline in QLQ-C30 or QLQ-OV28 domains overall (between-group difference in QLQ-C30 Global Heath Status [GHS] score = 1.65, 95% CI = \u22120.27 to 3.56) or in the homologous recombination deficiency\u2013positive subgroup (between-group difference in QLQ-C30 GHS = 1.23, 95% CI = \u22121.25 to 3.71). Time until definitive HRQoL deterioration estimates of QLQ-C30 GHS scores did not differ between treatment arms in the modified intention-to-treat population (hazard ratio [HR] = 0.88, 95% CI\u2009=\u20090.72 to 1.07) and favored olaparib plus bevacizumab vs placebo plus bevacizumab in the homologous recombination deficiency\u2013positive subgroup (HR\u2009=\u20090.70, 95% CI\u2009=\u20090.52 to 0.93). Analyses of patients (103 of 465 [22.2%]) following disease progression showed clinically meaningful deterioration in QLQ-C30 emotional and social scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding maintenance olaparib to bevacizumab showed no clinically meaningful detrimental effect on global HRQoL either overall or in the homologous recombination deficiency\u2013positive subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov ID<\/jats:title>\n                    <jats:p>NCT02477644.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag122","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:27:25Z","timestamp":1776770845000},"page":"1874-1887","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1\/ENGOT-ov25)"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-4942","authenticated-orcid":false,"given":"Florence","family":"Joly","sequence":"first","affiliation":[{"name":"Centre Fran\u00e7ois Baclesse, University Unicaen, Inserm U1086 Anticipe , Caen,","place":["France"]},{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-1367","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Anota","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-6867","authenticated-orcid":false,"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9412-5952","authenticated-orcid":false,"given":"Claire","family":"Cropet","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Priou","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"CHD Les Oudairies , La Roche Sur Yon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-5005","authenticated-orcid":false,"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[{"name":"Ev. Kliniken Essen-Mitte , Essen,","place":["Germany"]},{"name":"Philipps University , Marburg,","place":["Germany"]},{"name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Studiengruppe ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-2633","authenticated-orcid":false,"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS, \u2018Fondazione G Pascale\u2019 , Naples,","place":["Italy"]},{"name":"Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Palacio","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias , Oviedo,","place":["Spain"]},{"name":"Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario (GEICO) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Petru","sequence":"additional","affiliation":[{"name":"Medical University Graz , Graz,","place":["Austria"]},{"name":"Arbeitsgemeinschaft Gynaekologische Onkologie (AGO-Austria) ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-2189","authenticated-orcid":false,"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Kagoshima University Hospital , Kagoshima,","place":["Japan"]},{"name":"Gynecologic Oncology Trial and Investigation Consortium (GOTIC) ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"University Hospital Leuven, Leuven Cancer Institute , Leuven, Belgium, European Union"},{"name":"Belgium and Luxembourg Gynaecological Oncology Group (BGOG) , Belgium, European Union"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-0448","authenticated-orcid":false,"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[{"name":"European Institute of Oncology , Milan,","place":["Italy"]},{"name":"Mario Negri Gynecologic Oncology Group (MaNGO) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-6912","authenticated-orcid":false,"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[{"name":"Tampere University and University Hospital , Tampere,","place":["Finland"]},{"name":"Nordic Society of Gynecologic Oncology (NSGO) ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"Groupe Hospitalier Saint-Joseph , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7590","authenticated-orcid":false,"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Ev. Kliniken Essen-Mitte , Essen,","place":["Germany"]},{"name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Studiengruppe ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-6534","authenticated-orcid":false,"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS, \u2018Fondazione G Pascale\u2019 , Naples,","place":["Italy"]},{"name":"Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2900-2236","authenticated-orcid":false,"given":"Nuria","family":"Lainez","sequence":"additional","affiliation":[{"name":"Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario (GEICO) ,","place":["Spain"]},{"name":"Hospital Universitario de Navarra , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-3015","authenticated-orcid":false,"given":"Irina","family":"Tsibulak","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft Gynaekologische Onkologie (AGO-Austria) ,","place":["Austria"]},{"name":"Medical University Innsbruck , Innsbruck,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":false,"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Trial and Investigation Consortium (GOTIC) ,","place":["Japan"]},{"name":"National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-3722","authenticated-orcid":false,"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[{"name":"Belgium and Luxembourg Gynaecological Oncology Group (BGOG) , Belgium, European Union"},{"name":"CHU UCL Namur , Namur, Belgium, European Union"},{"name":"CHU Brugmann , Brussels, Belgium, European Union"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2998-4106","authenticated-orcid":false,"given":"Maria Teresa","family":"Lapresa","sequence":"additional","affiliation":[{"name":"Mario Negri Gynecologic Oncology Group (MaNGO) ,","place":["Italy"]},{"name":"European Institute of Oncology , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1010","authenticated-orcid":false,"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2111-4166","authenticated-orcid":false,"given":"Patrick","family":"Bouchaert","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"H\u00f4pital de la Mil\u00e9trie, Centre Hospitalier Universitaire de Poitiers, P\u00f4le R\u00e9gional de Canc\u00e9rologie , Poitiers,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-5635","authenticated-orcid":false,"given":"Paul","family":"Buderath","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Studiengruppe ,","place":["Germany"]},{"name":"West German Cancer Center, University Hospital Essen, Universit\u00e4tsklinikum Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) ,","place":["Italy"]},{"name":"Humanitas San Pio X and Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Herrero","sequence":"additional","affiliation":[{"name":"Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario (GEICO) ,","place":["Spain"]},{"name":"Hospital Universitario Miguel Servet , Zaragoza,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5954","authenticated-orcid":false,"given":"Lauriane","family":"Eberst","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"ICANS (Institut de Canc\u00e9rologie Strasbourg Europe) , Strasbourg,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9693-366X","authenticated-orcid":false,"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Studiengruppe ,","place":["Germany"]},{"name":"University Hospital, LMU Munich , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS and Universit\u00e0 Cattolica del Sacro Cuore di Roma , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-1125","authenticated-orcid":false,"given":"Eugenia","family":"Ortega","sequence":"additional","affiliation":[{"name":"Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario (GEICO) ,","place":["Spain"]},{"name":"Hospital Universitario Miguel Servet , Zaragoza,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Guillemet","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"Center Henri Becquerel , Rouen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[{"name":"ARCAGY Research , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"ICANS (Institut de Canc\u00e9rologie Strasbourg Europe) , Strasbourg,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) ,","place":["France"]},{"name":"Centre L\u00e9on B\u00e9rard, University Claude Bernard Lyon I , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026100903523320900_djag122-B1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","article-title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","volume":"22","author":"Friedlander","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026100903523320900_djag122-B2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ygyno.2022.06.028","article-title":"Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - pooled analysis from the PRIMA trial","volume":"166","author":"Chase","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2026100903523320900_djag122-B3","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100903523320900_djag122-B4","author":"AstraZeneca"},{"key":"2026100903523320900_djag122-B5","author":"AstraZeneca"},{"key":"2026100903523320900_djag122-B6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"2026100903523320900_djag122-B7","author":"ClinicalTrials.gov"},{"key":"2026100903523320900_djag122-B8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026100903523320900_djag122-B9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"key":"2026100903523320900_djag122-B10","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1111\/j.1524-4733.2007.00278.x","article-title":"Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group Experience","volume":"10(Suppl 2)","author":"Osoba","year":"2007","journal-title":"Value Health"},{"key":"2026100903523320900_djag122-B11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2026100903523320900_djag122-B12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2021.07.016","article-title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","volume":"163","author":"Colombo","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026100903523320900_djag122-B13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","article-title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"184","author":"Pothuri","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026100903523320900_djag122-B14","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026100903523320900_djag122-B15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.6004\/jnccn.2022.7101","article-title":"Evaluation of scores to reflect toxicity impact on quality of life of patients with platinum-resistant ovarian cancer: AURELIA substudy","volume":"21","author":"Lequesne","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026100903523320900_djag122-B16","doi-asserted-by":"crossref","first-page":"e17609","DOI":"10.1200\/JCO.2022.40.16_suppl.e17609","article-title":"Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19\/II)","volume":"40","author":"Harter","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100903523320900_djag122-B17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"key":"2026100903523320900_djag122-B18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study","volume":"32","author":"Vergote","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026100903523320900_djag122-B19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12553-025-00942-2","article-title":"Digital solutions supporting the quality-of-life of European cancer patients and their caregivers: a systematic literature review","volume":"15","author":"Ancona","year":"2025","journal-title":"Health Technol"},{"key":"2026100903523320900_djag122-B20","doi-asserted-by":"crossref","first-page":"27276","DOI":"10.1038\/s41598-024-78805-5","article-title":"Fatigue trajectories by wearable remote monitoring of breast cancer patients during radiotherapy","volume":"14","author":"Barillaro","year":"2024","journal-title":"Sci Rep"},{"key":"2026100903523320900_djag122-B21","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/IGC.0000000000000478","article-title":"European Network of Gynaecological Oncological Trial Groups\u2019 requirements for trials between academic groups and industry partners\u2014first update 2015","volume":"25","author":"Du Bois","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"2026100903523320900_djag122-B22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/IGC.0b013e3181d3caa8","article-title":"European Network of Gynaecological Oncological Trial Groups\u2019 requirements for trials between academic groups and pharmaceutical companies","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag122\/68157460\/djag122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1874\/68157460\/djag122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1874\/68157460\/djag122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:52:43Z","timestamp":1791532363000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/10\/1874\/8662328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag122","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,24]]}}}